Prime Medicine, Inc.
NASDAQ: PRME0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Allan Reine
- Employees
- 214
- Headquarters
- Cambridge, United States
- IPO year
- 2022
- Market cap
- $563.5M
- Website
- https://www.primemedicine.com
Loading PRME…
Loading profile data…Frequently asked questions about PRME
What does Prime Medicine, Inc. (PRME) do?
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzy...
Where does PRME trade?
Prime Medicine, Inc. (PRME) trades on the NASDAQ Global Market.
What sector is PRME in?
Prime Medicine, Inc. (PRME) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Prime Medicine, Inc.?
Allan Reine is the chief executive officer of Prime Medicine, Inc. (PRME).
Where is Prime Medicine, Inc. headquartered?
Prime Medicine, Inc. is headquartered in United States.
Does PRME pay a dividend?
Prime Medicine, Inc. (PRME) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PRME go public?
Prime Medicine, Inc. (PRME) completed its initial public offering in 2022.